Genscript Biotech Corporation
金斯瑞生物科技股份有限公司 *
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1548)

VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE

This is a voluntary announcement made by GenScript Biotech Corporation (the "**Company**", together with its subsidiaries, the "**Group**").

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, on 14 December 2020 (New York time), Legend Biotech Corporation ("**Legend Biotech**"), a non-wholly owned subsidiary of the Company, announced that the U.S. Food and Drug Administration (the "**FDA**") has cleared Legend Biotech's Investigational New Drug (the "**IND**") application to evaluate LB1901, the investigational autologous chimeric antigen receptor T-cell ("**CAR-T**") therapy, for the treatment of adults with relapsed or refractory T-cell lymphoma (TCL). Under the IND, Legend Biotech will initiate a Phase 1 clinical study for LB1901 in the United States.

LB1901 is an investigational CAR-T product targeting CD4, which is a surface membrane glycoprotein uniformly expressed in a majority of TCL subtypes. A Phase 1, first-in-human, open-label, multicenter, multicohort clinical study will enroll patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL) in the United States. The primary objectives of the study are to characterize the safety and tolerability of LB1901 and to determine the recommended Phase 2 dose.

TCL is a heterogeneous group of disorders accounting for less than 15 percent of Non-Hodgkin lymphoma cases in the United States. PTCL comprises subtypes which are uncommon and often aggressive, with a 5-year overall survival of 39% that varies by subtype. Cutaneous T-cell lymphomas are a group of T-cell malignancies, which occur primarily in the skin. Despite current treatment options, a substantial proportion of patients with PTCL or CTCL experiences relapse. A high unmet medical need remains for patients with relapsed or refractory PTCL and CTCL.

The FDA's clearance of Legend Biotech's IND application for LB1901 is a milestone representative of its scientific expertise in cell therapy innovation. Legend Biotech looks forward to working with the investigators as Legend Biotech explores its potential in meeting the unmet medical needs in the TCL population.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 14 December 2020

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* *For identification purposes only*